title: Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
abstract: Interleukin-2 is a remarkable activator of lymphocytes with anti-neoplastic properties such as T-cells or natural killer cells, but tumor regression only rarely occurs in interleukin-2-treated cancer patients. In this review, we focus on interactions between monocytes/macrophages and T-cells/natural killer-cells, and in particular the role of such interactions for the outcome of cancer immunotherapy with interleukin-2. We propose that interleukin-2 therapy should be supplemented with compounds that alleviate toxicity inflicted by monocyte/macrophage-derived reactive oxygen metabolites within and around tumors. The hypothesis is founded on data demonstrating that (i) functions of intratumoral lymphocytes in many human malignant tumors are inhibited by reactive oxygen metabolites, generated by neighboring monocytes/macrophages, (ii) interleukin-2 only weakly activates T-cells or natural killer cells in an environment of oxidative stress, and (iii) inhibitors of the formation of reactive oxygen metabolites or scavengers of reactive oxygen metabolites synergize with interleukin-2 to activate these lymphocyte subsets. We also review the preclinical background to the use of histamine dihydrochloride, an inhibitor of reactive oxygen metabolite formation in monocytes/macrophages, as a supplement to cancer immunotherapy with interleukin-2.
authors: Department of Virology, University of Göteborg, Sweden. kristoffer.hellstrand@microbio.gu.se
authors: K
authors: K
authors: Hellstrand
authors: M
authors: M
authors: Brune
authors: C
authors: C
authors: Dahlgren
authors: M
authors: M
authors: Hansson
authors: S
authors: S
authors: Hermodsson
authors: P
authors: P
authors: Lindnér
authors: U H
authors: UH
authors: Mellqvist
authors: P
authors: P
authors: Naredi
mesh_terms: D002450:Cell Communication; D004359:Drug Therapy, Combination; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000502:physiology; D016131:Lymphocyte Subsets; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D009000:Monocytes / Q000187:drug effects / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D018384:Oxidative Stress; D017382:Reactive Oxygen Species / Q000378:metabolism; D013601:T-Lymphocytes / Q000502:physiology
chemical_list: D007376:Interleukin-2; D017382:Reactive Oxygen Species; D006632:Histamine